Group | Average body-weight gain (g) | Relative body-weight gain (%) | Mean lesion scores | Decreased oocyst output (%) | ACI |
---|---|---|---|---|---|
Unchallenged control | 57.61 ± 9.47f | 100 | 0 ± 0a | 100.00 | 200 |
Challenged control | 36.89 ± 11.89ab | 63.68 | 2.63 ± 0.63fg | 0.00 | 97.30 |
pVAX1 control | 37.42 ± 6.82abc | 60.29 | 1.80 ± 0.38cdef | 8.91 | 102.24 |
Clone 8–2–2–1 | 41.76 ± 18.49abcde | 69.09 | 2.81 ± 1.50g | 56.44 | 130.97 |
Clone 8–2–2–2 | 48.83 ± 12.79cdef | 81.12 | 0.81 ± 0.62b | 51.49 | 162.97 |
Clone 8–2–2–3 | 40.12 ± 13.95abcd | 64.47 | 2.36 ± 1.24defg | 13.86 | 100.79 |
Clone 8–2–2–4 | 43.26 ± 14.30abcde | 73.50 | 2.84 ± 1.21g | 14.85 | 105.08 |
Clone 8–2–2–5 | 56.63 ± 26.03f | 93.89 | 1.66 ± 0.93bcde | 56.44 | 167.21 |
Clone 8–2–2–6 | 38.82 ± 11.68abcd | 63.52 | 1.92 ± 1.32cdef | 23.76 | 104.31 |
Clone 8–2–2–7 | 39.88 ± 18.61abcd | 66.43 | 2.78 ± 1.42g | 18.81 | 98.54 |
Clone 8–2–8–1 | 50.04 ± 19.32def | 84.86 | 1.26 ± 0.92bc | 52.48 | 162.22 |
Clone 8–2–8–2 | 48.27 ± 16.57bcdef | 80.03 | 1.50 ± 1.31bcd | 82.18 | 160.02 |
Clone 8–2–8–3 | 49.52 ± 18.54def | 85.80 | 1.57 ± 1.75bcd | 72.28 | 160.02 |
Clone 8–2–8–4 | 34.84 ± 14.24a | 60.28 | 1.52 ± 1.24bcd | 15.84 | 105.02 |
Clone 8–2–8–5 | 46.87 ± 12.41bcdef | 82.19 | 1.47 ± 1.19bc | 66.34 | 157.46 |
Clone 8–2–8–6 | 52.41 ± 15.10ef | 89.07 | 1.83 ± 1.24cdef | 60.40 | 160.74 |
Clone 8–2–8–7 | 39.89 ± 11.89abcd | 68.08 | 2.46 ± 1.14efg | 35.64 | 123.40 |